Global variations in cancer survival.
Population-based cancer registries from Algeria, China, Costa Rica, Cuba, India, the Philippines, and Thailand are collaborating with the International Agency for Research on Cancer in a study of cancer survival in developing countries.
Comparisons with the SEER program results of the National Cancer Institute in the United States, and the EUROCARE study of survival in European countries revealed considerable differences in the survival of patients with certain tumors associated with intensive chemotherapeutic treatment regimes (Hodgkin's disease and testicular tumors), more modest differences in the survival of patients with tumors for which early diagnosis and treatment confer an improved prognosis (carcinomas of the large bowel, breast, and cervix), and only slight differences for tumors associated with poor prognosis (carcinomas of the stomach, pancreas, and lung).
With limited resources to meet the challenge of the increasing incidence of cancer expected in the next few decades, health authorities in developing countries should be aware of the importance of investing in a range of cancer control activities, including primary prevention and early detection programs as well as treatment.
Mots-clés Pascal : Tumeur maligne, Hémopathie maligne, Homme, Pronostic, Survie, Epidémiologie, Pays en développement, Pays industrialisé, Analyse donnée, Interprétation
Mots-clés Pascal anglais : Malignant tumor, Malignant hemopathy, Human, Prognosis, Survival, Epidemiology, Developing countries, Industrialized country, Data analysis, Interpretation
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0055668
Code Inist : 002B04B. Création : 21/05/1997.